Lemaitre Vascular Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.6%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$276.5Mnext fiscal year
FY EPS (est.)
$2.88next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Sales Growth Quarterly1,000.0%Target: 12%
Gross Margin Quarterly7,270.0%Target: 72.3%
Operating Margin Quarterly2,700.0%Target: 29%
Artegraft OUS Revenue Annually
Watch Items
- Artegraft Manufacturing TransferTrigger: Delays in Chicago-to-Burlington facility transferAction: Assess impact on gross margins and supply chain continuity
- Sales Representative HeadcountTrigger: Declining sales rep count or failure to meet 2026 hiring targetsAction: Evaluate direct sales force productivity and geographic expansion execution
- EU MDR ComplianceTrigger: Delays in regulatory approvals for key product lines in EuropeAction: Monitor international sales growth and potential product backorders
Research as of 20 Jun 2026